03rd week of 2014 patent applcation highlights part 49 |
Patent application number | Title | Published |
20140018281 | CLEANING LIQUID AND ANTICORROSIVE AGENT - A method of cleaning a substrate having a metal layer including copper or a copper-containing alloy, the method including cleaning the substrate using a cleaning liquid that includes a mercapto compound represented by one or both of the following formulas (1) and (2), and a solvent containing water and a water-soluble organic solvent: | 2014-01-16 |
20140018282 | STORAGE-STABLE LIQUID WASHING OR CLEANING AGENT CONTAINING PROTEASE AND AMYLASE - According to the invention, storage stability in terms of amylolytic activity is to be improved in a liquid washing or cleaning agent which comprises a protease and amylase. This is achieved by the use of a protease which comprises an amino acid sequence which is at least 80% identical to the amino acid sequence specified in SEQ ID NO. 1 and which has the amino acid glutamic acid (E) or aspartic acid (D) or the amino acid asparagine (N) or glutamine (Q) or the amino acid alanine (A) or glycine (G) or serine (S) at position 99 in the count according to SEQ ID NO. 1. | 2014-01-16 |
20140018283 | Subtilase Variants - The present invention relates to novel subtilase variants exhibiting alterations relative to the parent subtilase in one or more properties including: Wash performance, thermal stability, storage stability or catalytic activity. The variants of the invention are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dishwash compositions, including automatic dishwash compositions. | 2014-01-16 |
20140018284 | DETERGENT COMPOSITIONS - Liquid aqueous detergent compositions comprising as thickeners and suspending agents crosslinked alkali swellable polyacrylates containing one or more acetoacetyl or cyanoacetyl groups. | 2014-01-16 |
20140018285 | DISPOSABLE AIR FRESHENER INCLUDING GEL OR POLYMER FRAGRANCE SUPPORT - Embodiments of the invention provide a fragrance distribution device comprising an electrical resistor, a plug or other power source, and a fragrance in a polymer or thermoplastic carrier. The polymer or thermoplastic carrier may include, for example, metal inclusions, which may be powdered metal. These metal inclusions are believed to enhance heat distribution throughout the carrier, thus allowing a more uniform and reliable release of fragrance. | 2014-01-16 |
20140018286 | AMYLIN ANALOGUES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 2014-01-16 |
20140018287 | BRIDGE-HELIX CAP: TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE - It has been discovered that the Sal target represents a new and promising target for antibacterial drug discovery. The Sal target is distinct from the rifamycin target and from the CBR703 target. This indicates that antibacterial compounds that function through the Sal target should exhibit no, or minimal, cross-resistance with rifamycins and CBR703. This further implies that it should be possible to co-administer antibacterial compounds that function through the Sal target together with a rifamycin, together with CBR703, or together with both a rifamycin and CBR703, in order to achieve additive or synergistic antibacterial effects and in order to suppress or eliminate the emergence of resistance. | 2014-01-16 |
20140018288 | X-DING-CD4 Peptide - Here provided are a pharmaceutical composition containing an X-DING-CD4 peptide, a derivative of the X-DING-CD4 peptide, or a combination thereof a method for preventing or treating a pathological condition in a subject using the above pharmaceutical composition; and a process of making the above pharmaceutical composition. Also provided are isolated X-DING-CD4 cDNAs and isolated X-DING-CD4 peptides. Further provided are the composition and method for cell-based therapy using polynucleotides encoding X-DING-CD4 peptide, its derivative, or a combination thereof. | 2014-01-16 |
20140018289 | New treatments of Hepatitis C virus infection - The disclosure concerns the use of cyclophilin inhibitors in the treatment of chronic Hepatitis C virus infection. | 2014-01-16 |
20140018290 | LEPTIN DERIVATIVES - The invention relates to Leptin derivatives, compositions and therapeutic use there-of. | 2014-01-16 |
20140018291 | METHODS FOR TREATING METABOLIC DISORDERS AND OBESITY WITH GIP AND GLP-1 RECEPTOR-ACTIVE GLUCAGON-BASED PEPTIDES - Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient. | 2014-01-16 |
20140018292 | METHOD OF INCREASING LIVER PROTEIN SYNTHESIS - A protein synthesis promoter that exhibits a protein synthesis-promoting effect includes a whey protein hydrolyzate having a molecular weight distribution that is within a range of 10 kDa or less and has a main peak of 200 Da to 3 kDa, an average peptide length (APL) of 2 to 8, a free amino acid content of 20% or less, a branched-chain amino acid content of 20% or more, and an antigenicity equal to or less than 1/100,000th of that of β-lactoglobulin. | 2014-01-16 |
20140018293 | MINIMIZING INTESTINAL DYSFUNCTION - Techniques are discloded for treating or reducing sumptoms associated with abdominal dysfunction or ileus following surgery or other abdominal episode by treating the area with a combination of one or more protease, antibacterial compound, and inflammatory lipid mediator. | 2014-01-16 |
20140018294 | NEUROGENIC BRAIN-DERIVED NEUROTROPHIC FACTOR PEPTIDES - Five tetra peptides corresponding to different active regions of brain derived neurotrophic factor (BDNF) that are neurotrophic and can modulate BDNF signaling in a partial agonist/antagonist way. The peptides offer a therapeutic approach to neural pathologies where BDNF levels are dysregulated. | 2014-01-16 |
20140018295 | NASAL DELIVERY - A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders. | 2014-01-16 |
20140018296 | LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided. | 2014-01-16 |
20140018297 | COMPOUNDS SUITABLE FOR TREATMENT OF HAEMOPHILIA - The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound. | 2014-01-16 |
20140018298 | CITRATE FREE PHARMACEUTICAL COMPOSITIONS COMPRISING ANAKINRA - The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment. | 2014-01-16 |
20140018299 | METHOD AND DEVICE TO DETECT, MONITOR AND PROMOTE NEURAL REGENERATION AND IMPROVEMENT OF COGNITIVE FUNCTION IN A SUBJECT SUFFERING FROM NEURAL INJURY - Severe traumatic brain (TBI) injuries are often associated with long-term and disabling consequences. Prognosis and chronic treatment planning following severe TBI remain challenging. The discovery of specific brain biomarkers could create new opportunities for more accurate clinical assessments identifying groups that may experience better outcomes when exposed to an intervention. The present invention provides a method of detection of Microtubule-associated protein-2 (MAP-2), a marker of dendritic damage, in a biological sample of survivors after TBI and evaluates the recovery of the patient, including an improvement in cognitive abilities and function. | 2014-01-16 |
20140018300 | NEUROPROTECTIVE AND NEURORESTORATIVE METHODS AND COMPOSITIONS - The invention relates to methods and products for preventing and treating neuronal cell death-associated diseases and/or conditions. The products and methods are useful for research and for clinical applications relating to neuronal cell-death associated diseases and/or conditions. | 2014-01-16 |
20140018301 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2014-01-16 |
20140018302 | Cancer Therapies and Diagnostics - Compositions and methods for increasing p53-dependent transcriptional activity in a cell. | 2014-01-16 |
20140018303 | 3-Amino-2-Hydroxy-4-Phenylbutanoyl-Valyl-Isoleucine, Preparation and Use Thereof - The present invention relates to a novel compound, 3-amino-2-hydroxy-4-phenylbutanoyl-valyl-isoleucine with structure showed below. | 2014-01-16 |
20140018304 | METHOD FOR SCREENING FOR A CANCER TREATMENT AGENT USING THE INTERACTION BETWEEN PAUF AND A BINDING PARTNER THEREOF - The present invention relates to a method for screening for a cancer treatment agent by contacting a test material with pancreatic adenocarcinoma upregulated factor (PAUF) and GLRX3, SNAPIN, or UBL4A, as a binding partner for PAUF, and then analyzing whether or not the test material inhibits the binding of the PAUF and GLRX3, SNAPIN, or UBL4A serving as a binding partner therefor, thereby determining that the test material is a cancer treatment agent if the binding is inhibited. The invention also relates to a pharmaceutical composition containing the test material as an active ingredient for inhibiting and treating cancer. The pharmaceutical composition of the present invention, which contains, as an active ingredient, an inhibitor for inhibiting PAUF from binding with a binding partner, effectively inhibits PAUF signaling related to the onset of cancer, thus enabling various kinds of cancer (especially pancreatic cancer) to be treated. | 2014-01-16 |
20140018305 | ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES FOR TREATING AGE-RELATED MACULAR DEGENERATION - Provided herein are compositions and methods for use in treating or preventing macular degeneration in a subject. | 2014-01-16 |
20140018306 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS - The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. | 2014-01-16 |
20140018307 | LINACLOTIDE COMPOSITIONS - The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions. | 2014-01-16 |
20140018308 | METHODS OF LOWERING BLOOD PRESSURE - Methods of improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as compounds and pharmaceutical compositions useful therein. | 2014-01-16 |
20140018309 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 2014-01-16 |
20140018310 | COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENTS L-CARNITlNE OR PROPIONYL L-CARNITlNE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY - A combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases. | 2014-01-16 |
20140018311 | MUSCADINE COMPOSITIONS WITH IMPROVED ANTI-OXIDANT ACTIVITY - Disclosed is a composition for use as an antioxidant, such as for use as an anti-aging supplement. The composition can include a muscadine ( | 2014-01-16 |
20140018312 | STEROID ALKALOIDS AND USES THEREOF AS ANTIMICROBIAL AGENTS AGAINST ELECTRON TRANSPORT-DEFICIENT MICROBES AND AS POTENTIATORS FOR ANTIMICROBIAL AGENTS AGAINST PATHOGENIC BACTERIA - The present invention includes novel compounds based on the tomatidine skeleton as well as composition comprising these compounds alone and in combination with known compounds, which exhibit antimicrobial activity against extracellular or intracellular electron transport-deficient microbes and/or increase the antimicrobial activity of aminoglycoside antibiotics against their targets, and which are useful as antibacterial agents for treatment or prophylaxis of monomicrobiotic or polymicrobic bacterial infections or for the reduction of antibiotic resistance development in animals or in humans, or for use as antiseptics or agents for sterilization or disinfection. | 2014-01-16 |
20140018313 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2014-01-16 |
20140018314 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 2014-01-16 |
20140018315 | DILUTE FILTRATION STERILIZATION PROCESS FOR VISCOELASTIC BIOPOLYMERS - Manufactured hyaluronic acid products are used in numerous surgical applications including viscoelastic supplementation for the treatment of osteoarthritis, however, traditional sterilization techniques result in the breakdown of such high molecular o weight viscoelastic biopolymers and are thus unsuitable. Disclosed are processes for obtaining concentrated sterile solutions of high molecular weight biopolymers such as hyaluronic acid. The processes include filter sterilization with a dilute preparation of the biopolymer, and concentration of the dilute filter sterilized biopolymer by ultrafiltration to a desired concentration. | 2014-01-16 |
20140018316 | OPHTHALMIC PHARMACEUTICAL COMPOSITION - The present invention has an object to provide an ophthalmic pharmaceutical composition, particularly, an ophthalmic solution, ophthalmic ointment, ophthalmic wash, intraocular infusion solution, wash for anterior chamber, internal medicine, injection, or preservative for extracted cornea, which has improved therapeutic and/or prophylactic effects on the swelling, edema and walleye/cloudiness in the lens and/or the cornea induced by ophthalmic diseases including cataract and which is safe and successively used for a relatively long period of time. The present invention solves the above object by providing an ophthalmic pharmaceutical composition incorporated with a saccharide having a basic structure consisting of four glucose molecules bound together in a cyclic manner via a specific binding fashion. | 2014-01-16 |
20140018317 | TARGETED NITROXIDE AGENTS - A compound having a structure of: | 2014-01-16 |
20140018318 | N1- and N2-CARBAMOYL-1,2,3-TRIAZOLE SERINE HYDROLASE INHIBITORS AND METHODS - The present invention provides inhibitors of a wide variety of serine hydrolase enzymes. The inhibitors of the present invention are N1- and N2-carbamoyl-1,2,3-triazole compounds such as those of Formula (I): | 2014-01-16 |
20140018319 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS - The invention provides compounds of Formula (I) | 2014-01-16 |
20140018320 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - There are disclosed compound of Formula (1): A | 2014-01-16 |
20140018321 | IMIDAZOLE PRODRUG LXR MODULATORS - Imidazole prodrugs, pharmaceutically acceptable salts, or isomers thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. | 2014-01-16 |
20140018322 | SYNERGISTIC ANTIMICROBIAL COMPOSITION - A synergistic antimicrobial composition comprising:
| 2014-01-16 |
20140018323 | SUSTAINED-RELEASE INJECTABLE FORMULATION - A composition which comprises a biologically active agent and a polymer that exhibits a reverse thermal gelation at a physiological temperature, in a carrier, and in which the active agent is in an undissolved form is disclosed herein. Further disclosed herein are methods utilizing the compositions for treating subjects, including non-human subjects, as well as kits for preparing and using a composition. The composition is preferably a sustained release formulation, and is particularly useful for treating animals, where single-dose treatment is desired. | 2014-01-16 |
20140018324 | METHOD FOR IMPROVING TETRACYCLINE-RESISTANCE OF ACINETOBACTER BAUMANNII - A method for improving tetracycline-resistance of | 2014-01-16 |
20140018325 | HIV PROTEASE INHIBITORS - Compounds of Formula I are disclosed wherein R | 2014-01-16 |
20140018326 | SULFONAMIDES AS HIB PROTEASE INHIBITORS - Compounds of Formula I are disclosed: wherein L, A, R | 2014-01-16 |
20140018327 | Pyrrole Derivatives as Nicotinic Acetylcholine Receptor Modulators for Use in the Treatment of Neurodegenerative Disorders Such as Alzheimer's and Parkinson's Disease - Disclosed is a compound of formula (I) wherein ‘a’ and R | 2014-01-16 |
20140018328 | Clear, Greaseless Skin Care Compositions - The present invention relates to compositions including anhydrous compositions which include a dimethicone crosspolymer and/or dimethicone elastomer gum and one or more skin care products which may include retinoic acid, retinoic acid derivatives, retinal, retinol and/or retinyl esters, and methods of making, storing, and using such compositions. | 2014-01-16 |
20140018329 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS IN THE TREATMENT OF NEOPLASMS - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases. | 2014-01-16 |
20140018330 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea - The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea. | 2014-01-16 |
20140018331 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM - The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided. | 2014-01-16 |
20140018332 | METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID - Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D | 2014-01-16 |
20140018333 | DIMER DIOL COMPOSITIONS AS SUBSTITUTES OF BODY FLUIDS - The invention relates to compositions containing at least 90% by weight of dimer diol for use in a method for the surgical or therapeutic treatment of the human or animal body, and in particular to the use thereof as a body fluid replacement substance. | 2014-01-16 |
20140018334 | Oral Dosage Forms of Bendamustine - In the present invention, there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide. | 2014-01-16 |
20140018335 | INDOLE DERIVATIVE, AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF - The present invention provides a compound represented by the general formula (I) of the present invention, which has EP | 2014-01-16 |
20140018336 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 - The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane. | 2014-01-16 |
20140018337 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 - The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane. | 2014-01-16 |
20140018338 | METHODS AND ASSAYS FOR TREATING FILOVIRIDAE INFECTIONS - Methods and assays for treating a subject with a filovirus infection using an agent that inhibits Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4. Methods for screening for an agent that treats and/or prevents infection of a subject with a filovirus, where the methods comprise determining whether the agent inhibits one or more of Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41. BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4, wherein an agent that inhibits one or more of NPCI, VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is a candidate for treating and/or preventing an infection with a filovirus and wherein an agent that does not inhibit NPCI, VPSII, VPSI6, VPSI8, VPS33A. VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is not a candidate for treating and/or preventing an infection with a filovirus. | 2014-01-16 |
20140018339 | METHODS FOR TREATING CHRONIC OR UNRESOLVABLE PAIN AND/OR INCREASING THE PAIN THRESHOLD IN A SUBJECT AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREIN - Methods are provided for reducing chronic inflammatory pain, increasing the levels of endogenous opioid peptides, as well as increasing the pain threshold of a subject having symptoms of androgen deficiency, comprising transdermally administering a composition comprising a bioactive androgen on a daily basis. In addition, the invention also relates to increasing the levels of endogenous opioid peptides in a human subject by administering an androgen composition to the subject. The invention also encompasses administration of a composition consisting essentially of an androgen for the treatment of chronic inflammatory pain, and for increasing the pain-threshold in a subject. | 2014-01-16 |
20140018340 | Insulin Mimetic Active Comprising Oxodiperoxo Vanadates and a Pharmaceutical Composition Obtained Thereof - A pharmaceutically acceptable peroxovanadium(v) amine product, DmpzH[VO(02)2](Dmpz)], and its oral as well as injectable use for the treatment of Diabetes mellitus, wherein the said therapeutically stable compound is obtained by reacting V205 or vanadate with hydrogen peroxide and the amine, dimethylpyrazole (Dmpz), at pH 5.5 and temperature 0-4° C. DmpzH[VO(02)2](Dmpz)] is thus poised as a versatile insulin mimic adapted for targeting insulin signaling, stimulating adipogenesis, abrogating insulin stimulated down stream signals thereby lowering the incidence of insulin resistance and type-2 diabetes. | 2014-01-16 |
20140018341 | METHOD OF INHIBITING TAU PHOSPHORYLATION - A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. | 2014-01-16 |
20140018342 | GAMMA SECRETASE INHIBITORS - Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease. | 2014-01-16 |
20140018343 | IRAK INHIBITORS AND USES THEREOF - The present invention provides arylo-fused thienopyrimidine compounds, compositions thereof, and methods of using the same. | 2014-01-16 |
20140018344 | AZAINDOLE DERIVATIVES - Disclosed are compounds of Formula 1, | 2014-01-16 |
20140018345 | INHIBITION OF ENZYMES - Compounds of formula (I): | 2014-01-16 |
20140018346 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER - Solid composition comprising (a) an anionic surfactant in combination with a water-soluble and basic polymer, or (b) a cationic surfactant in combination with a water-soluble and acidic polymer, and (c) at least one poorly water-soluble pharmaceutically active ingredient, and solid or liquid dosage forms, especially tablets, coated tablets, capsules or suppositories or aqueous solutions comprising the solid composition. The surfactant/polymer system is soluble in water and solubilises the active ingredient so that good bioavailability with therapeutical quantities may be attained. Aqueous solutions are suitable for nasal, parenteral or ophthalmic treatments. | 2014-01-16 |
20140018347 | BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE - The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural Formula (I) wherein the variables are as defined herein. | 2014-01-16 |
20140018348 | Composition and Method for Treatment of Depression and Psychosis in Humans - Compositions and methods tor the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMPAR antagonist. The present invention is also directed to methods for the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts. | 2014-01-16 |
20140018349 | Dosage Regimen, Medication Dispensing Package and Uses Thereof for the Treatment of Major Depressive Disorder - This invention provides an oral dosage regimen for the treatment of depression, a pharmaceutically acceptable medication dispensing package containing multiple dosage units of medicaments comprising an oral dosage regimen of D-cycloserine for the treatment of depression, a pharmaceutical composition comprising D-cycloserine formulated for oral administration providing a dosage of 1000 mg/day alone or in combination with antidepressant agents and uses thereof. | 2014-01-16 |
20140018350 | COMBINATION OF SULFONAMIDE COMPOUND AND TAFLUPROST - The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with tafluprost, their intraocular pressure lowering effects are complemented and/or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug. | 2014-01-16 |
20140018352 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2014-01-16 |
20140018353 | METHOD OF TREATING B-CELL MALIGNANT CANCERS AND T-CELL MALIGNANT CANCERS USING THIENOTRIAZOLODIAZEPINE COMPOUNDS - A method of treating B-cell malignant cancers or T-cell malignant cancers in a mammal by administering to a patient a pharmaceutically acceptable amount of a composition comprising (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo-[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide. The B-cell malignant cancers include diffuse large B-cell lymphoma and splenic marginal zone lymphoma. The T-cell malignant cancers include anaplastic large T-cell lymphoma. | 2014-01-16 |
20140018354 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS - The present invention provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR. The invention also provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR and modulators of the unfolded protein response. | 2014-01-16 |
20140018355 | LISOFYLLINE ANALOGS AND METHODS FOR USE - The present invention provides analogs of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and oral bioavailability than LSF. | 2014-01-16 |
20140018356 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula (I). | 2014-01-16 |
20140018357 | IRAK INHIBITORS AND USES THEREOF - The present invention provides thienopyridine compounds, compositions thereof, and methods of using the same. | 2014-01-16 |
20140018358 | BENZO [B] [1,4] OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS - Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors of Formula (I). | 2014-01-16 |
20140018359 | Niacin Mimetics, and Methods of Use Thereof - Disclosed are 6-(morpholinoalkyl)-substituted pyridines, and pharmaceutically acceptable salts and prodrugs thereof, that are active against a range of mammalian therapeutic indications. | 2014-01-16 |
20140018360 | AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS - The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer. | 2014-01-16 |
20140018361 | IRAK INHIBITORS AND USES THEREOF - The present invention provides furano- and pyrrolo-pyrimidine and pyridine compounds, compositions thereof, and methods of using the same. | 2014-01-16 |
20140018363 | 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS - Provided is a compound of the formula I or a pharmaceutically acceptable salt, solvate or stereoisomer thereof: | 2014-01-16 |
20140018364 | CHEMICAL COMPOUNDS - There is provided pyrimidinyl compounds of Formula (I), | 2014-01-16 |
20140018365 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS - The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof. | 2014-01-16 |
20140018366 | BITOPIC MUSCARINIC AGONISTS AND ANTAGONISTS AND METHODS OF SYNTHESIS AND USE THEREOF - Compositions for treating a condition associated with activity of a muscarinic receptor (e.g., one or more of M | 2014-01-16 |
20140018367 | IL-8 BIOMARKER - The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor. | 2014-01-16 |
20140018368 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES - The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer. | 2014-01-16 |
20140018369 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD - A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided. | 2014-01-16 |
20140018370 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 2014-01-16 |
20140018371 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto - The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single agent or in combination with one or more pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, or an alpha-glucosidase inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto. | 2014-01-16 |
20140018372 | CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE - A crystalline form of 3-{3-[1-(4-Dimethylaminomethyl-phenylamino)-1-phenyl-meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-6-yl}-propynoic acid ethylamide. | 2014-01-16 |
20140018373 | FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF - A fused heterocyclic compound the formula (1): wherein A | 2014-01-16 |
20140018374 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors - The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 2014-01-16 |
20140018375 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS - The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided. | 2014-01-16 |
20140018376 | Use of 1H-Quinazoline-2,4-Diones - The invention concerns the use of competitive AMPA receptor antagonists for the treatment, prevention or delay of progression of Rasmussen's encephalitis and/or certain forms of epilepsy. | 2014-01-16 |
20140018377 | Aminopropenoates as Fungicides - This application claims priority to European Patent Application No. 09173304.8, filed Oct. 16, 2009, and the benefit of U.S. Provisional Application No. 61/253,091, filed Oct. 20, 2009, the disclosure of each of which is incorporated by reference herein in its entirety. | 2014-01-16 |
20140018378 | POLYMORPHS OF METHYL (E)-2--3-METHOXYACRYLATE - The present invention relates to novel crystalline polymorphic and amorphous forms of the compound methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate (azoxystrobin). Infrared Raman spectra, X-Ray powder diffraction pattern and differential scanning calorimetry thermogram of two polymorphs “A” and “B” are provided. Further, the present invention also provides methods for preparing the novel polymorphic forms “A” and “B”, as well as processes for producing mixtures of the polymorphs, and a process for preparing amorphous azoxystrobin. Yet further, the present invention provides anti-fungal compositions comprising the novel crystalline polymorphs “A” and “B” or amorphous azoxystrobin, which are useful for controlling and combating fungi grown on agricultural and horticultural crops and up-land, and methods of using the same as pesticidal agents for combating fungi on agricultural and horticultural crops. | 2014-01-16 |
20140018379 | PYRIMIDINE DERIVATIVES - The present invention provides a compound of Formula I or Formula VI: | 2014-01-16 |
20140018380 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS - The present invention provides a new class of bicyclic heteroaryl compounds represented by Formula I, pharmaceutical compositions containing these compounds, and their use for modulating the activity of GPR119 in the treatment of metabolic disorders and complications thereof, as well as methods for the treatment of the metabolic disorders and complications thereof. | 2014-01-16 |
20140018381 | Use of Rosuvastatin Lactols as Medicaments - This invention relates to the discovery of novel rosuvastatin analogues. More specifically, the invention relates to novel rosuvastatin analogues which have utility in treating conditions treatable by the inhibition of HMG-CoA reductase. | 2014-01-16 |
20140018382 | Method for treament of neurologic dysfunction - A method for treatment of the symptoms of neurologic dysfunctions, including major depression, an autism spectrum disorder (ASD), and schizophrenia. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A. | 2014-01-16 |